Abstract:Background: Aging, noise, infection, and ototoxic drugs are the major causes of human acquired sensorineural hearing loss, but treatment options are limited. CRISPR/Cas9 technology has tremendous potential to become a new therapeutic modality for acquired non-inherited sensorineural hearing loss. Here, we develop CRISPR/Cas9 strategies to prevent aminoglycoside-induced deafness, a common type of acquired non-inherited sensorineural hearing loss, via disrupting the Htra2 gene in the inner ear which is involved in apoptosis but has not been investigated in cochlear hair cell protection. Results: The results indicate that adeno-associated virus (AAV)-mediated delivery of CRISPR/SpCas9 system ameliorates neomycin-induced apoptosis, promotes hair cell survival, and significantly improves hearing function in neomycin-treated mice. The protective effect of the AAV-CRISPR/Cas9 system in vivo is sustained up to 8 weeks after neomycin exposure. For more efficient delivery of the whole CRISPR/Cas9 system, we also explore the AAV-CRISPR/SaCas9 system to prevent neomycin-induced deafness. The in vivo editing efficiency of the SaCas9 system is 1.73% on average. We observed significant improvement in auditory brainstem response thresholds in the injected ears compared with the non-injected ears. At 4 weeks after neomycin exposure, the protective effect of the AAV-CRISPR/SaCas9 system is still obvious, with the improvement in auditory brainstem response threshold up to 50 dB at 8 kHz. Conclusions: These findings demonstrate the safe and effective prevention of aminoglycoside-induced deafness via Htra2 gene editing and support further development of the CRISPR/Cas9 technology in the treatment of non-inherited hearing loss as well as other non-inherited diseases.

Neonatal AAV gene therapy rescues hearing in a mouse model of SYNE4 deafness

Combined AAV-mediated gene replacement therapy improves auditory function in a mouse model of human DFNB42 deafness

Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice

AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration

Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8

Virally Mediated Kcnq1 Gene Replacement Therapy in the Immature Scala Media Restores Hearing in A Mouse Model of Human Jervell and Lange-Nielsen Deafness Syndrome

Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction

Gene therapy for deafness

Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss

Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease

AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives

Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction

Prevention of acquired sensorineural hearing loss in mice by in vivo <i>Htra2</i> gene editing

Early postnatal virus inoculation into the scala media achieved extensive expression of exogenous green fluorescent protein in the inner ear and preserved auditory brainstem response thresholds.

AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness

Gene Therapy for Human Sensorineural Hearing Loss

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

Hearing restoration by gene replacement therapy for a multisite-expressed gene in a mouse model of human DFNB111 deafness

Gene editing in a Myo6 semi-dominant mouse model rescues auditory function

Considering gene therapy to protect from X-linked deafness DFNX2 and associated neurodevelopmental disorders

AAV2.7m8 is a powerful viral vector for inner ear gene therapy